share_log

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target

Benzinga ·  Dec 20, 2023 10:27

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $152 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment